Sponsored by Merck KGaA, Darmstadt, Germany
Oct 2024
The webinar will present a novel study that explores the impact of Multiple Sclerosis (MS) on patients’ health and overall well-being, highlighting the importance of early access to disease-modifying treatments (DMTs) with convenient administration.
Oct 2024
Drs. Inma Hernandez and Sean D. Sullivan will compare the recently published Medicare Maximum Fair Prices (MFPs) with net prices before negotiation to discuss the potential magnitude of savings achieved by negotiation. Drs. John O’Brien of the National Pharmaceutical Council and Greg Daniel of Eli Lilly will provide additional context for the MFPs and the estimated cost savings projections. This session will be highly relevant for professionals and researchers in market access, pricing, and HEOR.
Jun 2024
Hear from ISPOR’s Chief Science Officers, who will begin with the methods underlying the report, and then will discuss each of the Top 10 topics, the HEOR considerations related to each one, and how ISPOR members are engaged in them, and will conclude with a question and answer period.
May 2024
The webinar will begin with an introduction of the participants of the study to the ISPOR Rare Disease (RD) SIG, followed by an overview of the study objectives, its methodology and findings. The novel study explored the burden of different RDs across a range of countries, including low-and-middle-income countries (LMICs). The diseases and countries were chosen to allow for a diverse and relevant representation of RD burden globally, aiming to capture cross-disease and cross-country unmet needs, and consequent areas for policy intervention.
Oct 2023
The aim of this webinar is to discuss real-life examples on how biosimilar adoption has positively impacted care and patient access to biological therapies, focusing on testimonies from patient, policy, and healthcare professional representatives. Speakers are invited to converse on what the tangible benefits are that biosimilars have delivered for patients, and how biosimilar availability has supported access to care and the implementation of optimized disease management initiatives.
Sponsored by FIFARMA
Jul 2023
This webinar will inaugurate the third edition of the series of webinars sponsored by FIFARMA on Value and Access to Innovation, and will be focused on exploring the relationship between health and the economy and how to ensure the long term healthcare system sustainability.
Jun 2023
This webinar is aimed at all those who undertake research and development as well as value assessment of therapies and diagnostics in the rare disease space. It aims to expose the “diagnostic odyssey” and explain why a definitive diagnosis is not only important for patients but also for those assessing value. Objectives are to 1) explain what can be done to improve diagnosis in rare diseases and 2) why it matters in the context of value assessment.
Sponsored by Charles River Associates
Oct 2022
Biosimilars offer great potential for the patients, payers and the whole society. However, there exist policy barriers which can hinder this potential. The debate will analyze the challenges and opportunities for biosimilars uptake in Europe, Middle East and Canada.
Oct 2022
Many health systems in Africa are generally characterized by high burden of out-of-pocket payment by patients at the point of care and increased exposure of clients to catastrophic health payments. However, there are recent moves by many African countries to improve their health financing systems and institute health insurance in a bid to ensure universal health coverage.
Sponsored by FIFARMA
Oct 2022
This webinar will focus on discussing how to ensure access for the right patient, to the right treatment, at the right time. We invited Max Newton, Engagement Manager at IQVIA as guest speaker. Max worked on the development of the FIFARMA "Patients Waiting to Access Innovative Therapies (WAIT) Indicator survey"; he also is leading a similar survey in Europe, the "EFPIA WAIT indicator".
Sponsored by Replica Analytics
Sep 2022
This webinar presents a brief tutorial on synthetic data generation, an overview of its privacy preserving properties, and then review the results from studies evaluating the validity of analyses using synthetic data.
Sponsored by Charles River Associates
Sep 2022
This webinar leverages recent global research conducted across 17 countries to provide an overview of the challenges and solutions to ensure the biosimilar benefits are sustainably delivered to the whole society. There will be a specific focus on the issues in Australia and comparing those against examples found globally. Implications for patients, society as well as a discussion of the learnings in terms of policy provisions and best practices that can help solving these issues will also be held.
Sponsored by FIFARMA
Aug 2022
This is the Second webinar of the Value and Access to Innovation webseries sponsored by FIFARMA. The series are structured around FIFARMA's VAI working group workstreams: (1) Funding: what is the relation between health & the economy and how to ensure the long term healthcare system sustainability, (2) Value: what are the value frameworks used by decision makers in LatAm and what is the impact on patient access, (3) Adoption: how to ensure access for the right patient, to the right treatment, at the right time.
Jul 2022
The key success factor for digital health implementation is the information sharing across multiple stakeholders engaged in the clinical decision making. The COVID pandemic revealed numerous differences in how individual data are used in the process of the adoption of various digital health solutions in the healthcare systems across the globe.
Sponsored by FIFARMA
Jul 2022
This is the first webinar of the Value and Access to Innovation webseries sponsored by FIFARMA. The series are structured around FIFARMA's VAI working group workstreams.
Jun 2022
This webinar will aim to provide an educational opportunity for the ISPOR membership to learn about the methods for conducting distributional cost-effectiveness analysis (DCEA).
Sponsored by AstraZeneca
Jun 2022
For cancer drugs, payers often prefer to make decisions based on overall survival (OS) outcomes. However, it may take many years to collect OS data; this is particularly apparent in early-stage cancer and when an active therapy is highly effective at extending life.
Sponsored by Charles River Associates
Jun 2022
This webinar leverages recent global research conducted across 17 countries to provide an overview of the challenges and solutions to ensure the biosimilar benefits are sustainably delivered to the whole society.
Sponsored by Merck & Co., known as MSD outside the United States and Canada
May 2022
Next-generation sequencing (NGS) is the key to precision medicine in oncology and delivers several benefits across the patient care pathway, from providing patients with a tailored therapeutic strategy, increasing efficiency in healthcare systems delivery of care, resulting in potential cost savings and benefits to future patients.
Apr 2022
Health systems in Asia Pacific regions are under tremendous pressure to deal with the rising costs, unequal access to service, and uneven quality of care. More and more healthcare systems across the region have increasingly embraced a value-based health care (VBHC) agenda. How can we maximize value for money and optimize patient outcomes? How should healthcare be delivered and reimbursed? In light of these issues, this webinar brings together a panel of experts to discuss the current situation of value-based payment in the Asia Pacific region and beyond, challenges and opportunities for VBHC implementation in the region.
Sponsored by Biogen
Apr 2022
This session educates about the specific challenges of rare disease treatments in an HTA and discusses how Real-World Evidence Collection can address the data gap at the time of access decision.
Apr 2022
The key success factor for digital health implementation is the information sharing across multiple stakeholders engaged in the clinical decision making. The COVID pandemic revealed numerous differences in how individual data are used in the process of the adoption of various digital health solutions in the healthcare systems across the globe.
Mar 2022
This session will discuss trends in the HTA/Reimbursement environment in Latin America and the drivers for value-based health care (VBHC) implementation within the region. The potential benefits of VBHC, stakeholders’ roles in VBHC, contextual barriers and facilitators for VBHC implementation, and potential future impact of VBHC to healthcare in the region will be discussed by a panel of speakers.
Sponsored by Medtronic
Mar 2022
Experts from around the world will be sharing their experience about obesity treatment and reimbursement policies in their different countries. The event will consist of 7 expert presentations followed by a round table discussion with an opportunity for the audience to ask questions.
Jan 2022
This webinar emerges in the sequence of relevant topics highlighted in the ISPOR Science Strategy (particularly the Special Populations and Technologies and Health Economics, Access and Policy sections) and the Special Interest Group on biosimilars, by specifically reflecting on how to tackle inefficiencies of healthcare systems in the future with biosimilars.
Mar 2021
This webinar will review each of the theme areas and focal points in the Strategy, the process by which they were generated, and their potential implications for future ISPOR activities.
Mar 2021
To help viewers better understand the region, this webinar brings together a panel of health experts across Latin America to provide multiple perspectives on the effects of COVID-19 in the healthcare of Latin America including regulatory change and innovation, public-private partnerships in health, digital transformation, regional and inter-regional cooperation and capacity building. Brought to you by ISPOR's Latin America Consortium.
Sponsored by FIFARMA
Mar 2021
En este evento educativo, escucharemos a dos expertos que han estado a la vanguardia de los esfuerzos en America Latina por implementar estos acuerdos, con el fin de balancear el acceso a nuevas tecnologías con un financiamiento sostenible. Héctor Castro (Líder global en financiamiento a la salud, tecnologías, datos e impacto, MSH) y Alicia Ferreira (Ex-directora del Fondo Nacional de Recursos) compartirán con nosotros ejemplos reales de cómo los Acuerdos de Entrada Gestionada se están implementando progresivamente en América Latina y, recomendaciones sobre cómo crear las bases para un camino mejorado hacia un mayor acceso a tratamientos para todos los latinoamericanos.
Feb 2018